Evaluating Length of Treatment With PD-1/PD-L1 Inhibitor in Advanced Solid Tumors
Latest Information Update: 28 Mar 2025
At a glance
- Drugs Atezolizumab (Primary) ; Ipilimumab (Primary) ; Nivolumab (Primary) ; Pembrolizumab (Primary)
- Indications Advanced breast cancer; Anal cancer; Bladder cancer; Cervical cancer; Cholangiocarcinoma; Colon cancer; Gastric cancer; Head and neck cancer; Liver cancer; Malignant melanoma; Merkel cell carcinoma; Non-small cell lung cancer; Oesophageal cancer; Ovarian cancer; Rectal cancer; Renal cancer; Solid tumours; Squamous cell cancer; Uterine cancer
- Focus Therapeutic Use
Most Recent Events
- 25 Mar 2025 Planned End Date changed from 1 Oct 2028 to 30 Nov 2031.
- 25 Mar 2025 Planned primary completion date changed from 1 Oct 2028 to 30 Nov 2030.
- 19 Mar 2024 Planned End Date changed from 1 Oct 2026 to 1 Oct 2028.